Clinical trial · no report yet · Phase 2
FOOTPATH
First-line Therapy in Metastatic PDAC
- NCT03487016 ↗
- Unknown
- Ludwig-Maximilians - University of Munich
- 12 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 9 | |
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter Randomized Phase II Study to Determine the Optimal First-line Chemotherapy Regimen in Patients With Metastatic Pancreatic Cancer
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Gemcitabine; Nab-paclitaxel; 5-FU; Irinotecan Liposomal Injection; Oxaliplatin
- Arms
- A: Gemcitabine/nab-Paclitaxel (Standard) · Active comparator
- B: NAPOLI regimen · Experimental
- C: seq-NAPOLI-FOLFOX · Experimental
- Enrollment
- 270
- Primary outcomes
- Progression-free survival
- Sponsor
- Ludwig-Maximilians - University of Munich
- Start
- Feb 15, 2019
- Primary completion
- Jul 1, 2022
- Results posted
- No
- Registry record
- NCT03487016 · updated Sep 8, 2022